Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
January 16, 2026 Off

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

By GlobeNewswire

All resolutions passed, enabling the Company to streamline regulatory and operational processesSAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) — Oncolytics…

January 16, 2026 Off

Metabo Drops Investigated: Is It Worth It in 2026? Truth Behind the Liquid Metabolism Drops

By GlobeNewswire

New York City, NY, Jan. 15, 2026 (GLOBE NEWSWIRE) — As metabolism supplements continue to grow in popularity in 2026,…

January 16, 2026 Off

Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting

By GlobeNewswire

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE15 JANUARY 2026 at 16:30…

January 16, 2026 Off

Adaptin Bio to Present at the 2026 Sequire Investor Summit in Puerto Rico

By GlobeNewswire

CHARLOTTE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) — Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company focused on…

January 16, 2026 Off

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

By GlobeNewswire

The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc”…

January 16, 2026 Off

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

By GlobeNewswire

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately…

January 16, 2026 Off

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

By GlobeNewswire

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no…

January 16, 2026 Off

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

By GlobeNewswire

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”),…

January 16, 2026 Off

HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting

By GlobeNewswire

Company Shared Poster on Breakthrough Genetic Stratification Data from Positive Phase 2b OLIVE Trial Results for BH-200MUNICH, Germany, Jan. 15,…

January 16, 2026 Off

ViroMissile Appoints Michael G. Wood as Chief Business Officer

By GlobeNewswire

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic…

Posts pagination

Previous 1 … 14 15 16 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine